Jefferies Remains Bullish on Arena Pharma (ARNA) But Tempers Valuation Target on Data from Rival
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Slashes Numbers on Vivus (VVUS) on Slow Qsymia Uptake; Sees Another 45% Downside
November 7, 2012 12:33 PM ESTJefferies slashed its price target on Underperform-rated Vivus (NASDAQ: VVUS) Wednesday from $13 to $6 to reflect the slow Qsymia uptake.
VVUS disclosed that there have been 5,560 Qsymia prescriptions shipped through October 26. This is 30% below the IMS data (7,865 after applying adjustment factors) and SHA (formerly Wolters Kluwer) data... More
Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of 7c/Share
November 6, 2012 4:07 PM ESTArena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $3.51 million.
Updates:
Eisai Inc. beginning to market BELVIQ in the United States in early 2013,... More
VIVUS (VVUS) Ticks Lower; Wider Q3 Loss Attributed to Qsymia Launch, Expansion (ARNA) (OREX)
November 6, 2012 8:56 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is trading higher in early action following third-quarter results issued earlier.
Though revs were just $41 million, VIVUS noted that, "[g]iven the lack of history in selling Qsymia, VIVUS will recognize revenue on the sell-through method, that is, revenue is recognized as prescriptions... More
